Disease Modelling Services

In vitro retinal disease modelling for retinal therapy. Newcells offers a fast and reliable in vitro safety and efficacy service for the evaluation of novel compounds for retinal therapy using complex human retinal organoid or RPE models developed in house. Both models are iPSC derived allowing gene-edited lines to be engineered using CRISPR/Cas9 for direct comparison between WT and mutant phenotypes after differentiation. Targeted mutations can model retinopathies, more specifically monogenic inherited retinopathies such as retinitis pigmentosa (RP), Stargardt disease, Usher’s syndrome and Leber congenital amaurosis.